Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Carcinoma, Renal Cell 30Carcinoma, Non-Small-Cell Lung 16Melanoma 15Prostatic Neoplasms 13Stomach Neoplasms 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 9Kidney Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Neoplasms 7Neoplasm Metastasis 6Lung Neoplasms 6Breast Neoplasms 6Ovarian Neoplasms 5Carcinoma, Merkel Cell 5Urologic Neoplasms 4Pancreatic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Neuroendocrine Tumors 2

Interventions

pembrolizumab 3Nivolumab 3atezolizumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Microsatellite Instability × atezolizumab × Genitourinary × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡